logo

For the Inventor, By the Inventor

Houston, TX, United States of America

Shu-Hsia Chen

LinkedIn

This inventor holds 7 USPTO granted patents and 5 published patent applications. Top assignees: Icahn School of Medicine at Mount Sinai, Baylor College of Medicine, The Methodist Hospital. Active years: 1997-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shu-Hsia Chen. Retrieved from https://idiyas.com/inventor/shu-hsia-chen-51iyaees

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 7 

% Patents Active = 85.7

Average Co-Inventor Count = 1.6

ph-index = 3

Forward Citations = 168(Granted Patents)


Location History:

  • Houston, TX (US) (1997 - 2001)
  • New York, NY (US) (2015 - 2023)

Company Filing History:

goldMedal4 out of 538 
 
Icahn School of Medicine at Mount Sinai
 patents
silverMedal3 out of 619 
 
Baylor College of Medicine
 patents
bronzeMedal1 out of 50 
 
The Methodist Hospital
 patents
where one patent can have more than one assignee

Years Active: 1997-2024

Loading Chart...
7 patents (USPTO):Explore Patents
1. 12157768 - Anti-LILRB2 antibodies and methods of use thereof (2024-12-03),
2. 11787858 - Anti-LILRB3 antibodies and methods of use thereof (2023-10-17),
3. 9352006 - Methods and compositions for treating tumors using myeloid derived suppressor cells (2016-05-31),
4. 8951529 - Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases (2015-02-10),
5. 6217860 - Gene therapy for solid tumors, papillomas and warts (2001-04-17),
6. 6066624 - Gene therapy for solid tumors using adenoviral vectors comprising (2000-05-23),
7. 5631236 - Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or (1997-05-20),

Title: Innovations of Shu-Hsia Chen in Antibody Development

Introduction

Shu-Hsia Chen is a prominent inventor based in Houston, TX, known for her significant contributions to the field of antibody research. With a total of 7 patents, she has made remarkable strides in developing antibodies that target specific proteins involved in various diseases.

Latest Patents

Among her latest patents are the "Anti-LILRB2 antibodies and methods of use thereof." This patent discloses antibodies and antibody fragments that specifically bind to LILRB2. The patent also includes compositions comprising these antibodies and methods of use, such as targeting tumors, treating asthma, and removing infected cells. Another notable patent is the "Anti-LILRB3 antibodies and methods of use thereof," which similarly focuses on antibodies that bind to LILRB3 and their applications in medical treatments.

Career Highlights

Shu-Hsia Chen has worked at prestigious institutions, including the Icahn School of Medicine at Mount Sinai and Baylor College of Medicine. Her work has significantly advanced the understanding and application of antibodies in therapeutic settings.

Collaborations

Throughout her career, she has collaborated with notable professionals, including Savio L Woo and Savio L C Woo, enhancing the impact of her research through teamwork and shared expertise.

Conclusion

Shu-Hsia Chen's innovative work in antibody development has the potential to transform treatments for various diseases, showcasing her importance in the field of biomedical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…